09:59 AM EST - HLS Therapeutics Inc. : Updates investors that Vascepa® (icosapent ethyl, or "IPE") will become available to Canadians on or about February 18. At launch, Vascepa will be supported by the Company's national Cardiovascular salesforce, initially sized at 22 representatives, in addition to eight other field-based roles. HLS Therapeutics Inc.
shares T.HLS are trading up $0.30 at $23.00.
